Scientific Program

Wed

Thu

Fri

Sat

Wednesday, April 26, 2023
BREAST CANCER

sponsor of the day 04 26 astra zeneca

08:20 am
Welcome Adress of the Hosts and Greeting Words
J.-U. Blohmer and J. Sehouli
08:30 am
12.30 pm
Lunch Break

SYMPOSIUM (With kind support of AstraZeneca)
Paradigm Shift in Breast Cancer?
Chair: J.-U. Blohmer

01:00 pm
BRCAm Tumours – The Next Subtype?
D. Speiser
01:20 pm
New Approaches in Metastatic Breast Cancer – HER2-Low and HR-Positive
J. U. Blohmer
01:40 pm
Q & A

PRESIDENTIAL LECTURES
Chairs: D. Speiser, F. Reyal

01:50 pm
New Strategies for Management of Patients with ER+/HER2-Breast Cancer and Progression on CDK 4/6
Inhibitors: From Targeted Therapies to ADC
M. P. Goetz
02:10 pm
Do We Need More Technologies in Breast Surgery and Breast Reconstruction Like OPS, TAD, TAS, ICG-A, Synthetic Meshes, ADMs?
J.-U. Blohmer

STATE OF THE ART SESSION
Chairs: R. Leon Ferre, S. Kümmel

02:30 pm
Precision Surgery in Breast Cancer – Visualizing Breast Tumor Placement and Extent
F. Reyal
02:50 pm
Hereditary Breast Cancer – Treatment of Early and Advanced Breast Cancer
D. Speiser

READY FOR PRIME TIME?
Chairs: V. Kiver, T. Haddad, D. Kaul

03:10 pm
Alarmbased PRO Monitoring – Ready for Clinical Implementation for All?
M. Karsten
03:30 pm
Conventional Versus Hypofractionated Post-Mastectomy Proton Radiotherapy in HR-Deficient Tumors
R. Mutter
03:50 pm
Coffee Break

IMPORTANT AND ACTUAL QUESTIONS AND TOPICS
Chairs: M. P. Goetz, J.-U. Blohmer

04:20 pm
De-Escalation of Therapy in the Elderly Necessary and Possible?
A. Lee
04:35 pm
Moving Clinical Trials to Home: Home-Based Care
T. Haddad
04:50 pm
Patient-Derived Xenografts and/or Cancer Genom Sequence: Ready for Clinical Practice?
V. Kiver
05:05 pm
What is Low-HER2 and Does it Matter in Clinical Decision?
S. Kümmel
05:20 pm
New Strategies in the Neoadjuvant and Metastatic Setting for Triple-Negative Breast Cancer
R. Leon Ferre
05:35 pm
New Models to Understand Unique Biology and Treatment Response in Invasive Lobular Carcinoma
S. Oesterreich
05:50 pm
Development of a Breast Cancer Vaccine for Primary Prevention of Breast Cancer
K. Knutson
06:05 pm
Discussion
all speakers
06:30 pm
End of Program
agsdi-bookmark-star

CMC Master Course

Parallel to main program (04:00 pm to 06:00 pm)

Surgical and Medical Management in Ovarian Cancer
J. Sehouli, S. Dowdy, C. Fotopoulou

Thursday, April 27, 2023
CERVICAL, ENDOMETRIAL CANCER, SARCOMA

sponsor of the day 04 27 eisei

08:30 am
12.30 pm
Lunch Break

COLLOQUIUM (Funded by Eisai Europe Ltd.)
Priming and Practical Optimal Management Before, During and After Immunotherapy in Endometrial Cancer

01:00 pm
Distillation of current standard of care in immunotherapy
N. Concin
01:10 pm
How to prepare patients before therapy?
J. Sehouli
01:20 pm
How to monitor patients during therapy?
B. Monk
01:30 pm
Long-term survivors in endometrial cancer – who they are
R. Coleman
01:40 pm
Panel Discussion
N. Concin, B. Monk, R. Coleman, J. Sehouli

CERVICAL CANCER
Chairs: K. Pietzner, S. Dowdy, W. Lichtenegger

PRESIDENTIAL LECTURE

01:50 pm
How to Treat Best Advanced and Metastatic Cervical Cancer
D. Cibula

OVERVIEW

02:10 pm
Best of Global Clinical Trials: Current and Planned Studies
E. Roser
02:15 pm
CMC Exclusive! First Scientific Presentation: Charité Experience Regarding Alustents
J. Neymeyer, R. Armbrust

PRO/CON DEBATE

02:20 pm
Open Versus Minimally Invasive Surgery in Cervical Cancer: Where are We Now After 5 Years of LACC?
Open Surgery: C. Marth
Minimally Invasive Surgery: G. Scambia
Discussion: M. Z. Muallem, C. Marth, G. Scambia
03:00 pm
Coffee Break

ENDOMETRIAL CANCER, SARCOMA
Chairs: A. Mariani, R. Chekerov, D. Lorusso

PRESIDENTIAL LECTURE

03:30 pm
New Standards in Advanced and Metastatic Endometrial Cancer
M. R. Mirza

OVERVIEW

03:50 pm
Best of Global Clinical Trials: Current and Planned Studies
T. Arndt

DEBATE

04:00 pm
Sentinel Node Biopsy
Who Should Get It?
N. Abu-Rustum
Who Not?
A. Mariani
Discussion

HOTTEST TOPICS IN CLINICAL ROUTINE AND RESEARCH

04:40 pm
Newest Insights of Robotic Assisted Surgery in Endometrial Cancer
M. Z. Muallem
05:00 pm
onsequence for Clinical Day and Science: Checkpoint Inhibitor after Checkpoint Inhibitor – Who Benefits, Who Not, How to Modify the Therapy?
D. Lorusso
05:20 pm
Molecular Characterization in Endometrial Cancer: What are the Definitions, What are the Limitations?
E. Taube
05:40 pm
What is the Best Therapy for Wild-Type and Mutant P53 Tumors?
J. Sehouli
06:00 pm
Dostarlimab Plus Chemotherapy for the Treatment of Primary Advanced or Recurrent (A/R) Endometrial Cancer (EC): A Placebo (PBO)-Controlled Randomised Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
L. Hanker
06:20 pm
Discussion
all speakers
06:30 pm
End of Program
agsdi-bookmark-star

CMC Master Course

Parallel to main program (04:00 pm to 06:00 pm)

Surgical and Topographic Anatomy: Breast Cancer and Reconstructive Surgery
J.-U. Blohmer, O. Camara, S. Paepke, F. Reyal

Friday, April 28, 2023
OVARIAN CANCER

sponsor of the day 04 28 gsk

08:30 am
12:30 pm
Lunch Break

SYMPOSIUM (With kind support of GlaxoSmithKline)
Rethinking Ovarian Cancer Treatment – From Ideas to Practice. Where are we Today? What are New Concepts for Tomorrow?
Chair: P. Harter

01:00 pm
Brief Introduction
P. Harter
01:10 pm
Surgery – Challenging Optimal Timing
P. Wimberger
01:20 pm
Chemotherapy – Challenging Historical Paradigms
K. Pietzner
01:30 pm
Maintenance Therapy – Rethinking the Backbone
J. Sehouli
01:40 pm
Summary
P. Harter

OVARIAN CANCER I
Chairs: C. Marth, A. Wahner-Hendrickson, M. R. Mirza

 

PRESIDENTIAL LECTURE

01:50 pm
How to Treat Best Advanced Ovarian Cancer?
T. Herzog
 

OVERVIEW

02:10 pm
Best of Global Clinical Trials: Current and Planned Studies
R. Armbrust
02:15 pm
CMC Exclusive! First Scientific Presentation: 20 Years Experience in Ovarian Cancer Surgery – Charité Berlin
J. Sehouli
 

HOTTEST TOPICS IN CLINICAL ROUTINE AND RESEARCH

02:20 pm
What Can HRD Testing Really Predict, What Not?
S. Weroha
02:40 pm
Real-World Evidence in Advanced Ovarian Cancer and its Clinical Implication
J. Sehouli
03:00 pm
Current and Future Options for Patients with Relapsed Ovarian Cancer
A. Wahner-Hendrickson
03:20 pm
Newest Insights of Immunotherapy in Gynecological Malignancies
B. Monk
03:40 pm
Coffee Break

OVARIAN CANCER II
Chairs: J. Sehouli, C. Fotopoulou, S. J. Weroha

 

LECTURES

04:10 pm
HIPEC, PIPAC and More – Where is their Real Place?
P. Harter
04:30 pm
Surgical and Conservative Management of Bowel Obstruction in Ovarian Cancer
C. Fotopoulou
04:50 pm
Secondary Malignancies: How to Prevent, How to Treat Best?
L. Bullinger
05:10 pm
PARP After PARP Therapy: Who Can Really Benefit, Who Not?
J. Ledermann
05:30 pm
Endometriosis-associated Ovarian Cancer and its Clinical Implications
S. Mechsner
05:50 pm
Discussion
all speakers
06:00 pm
End of Program
agsdi-bookmark-star

CMC Master Course

Parallel to main program (05:30 pm to 07:30 pm)

Prerehabilitation, ERAS, Minimally Invasive Complication Management, Blood Management
S. Dowdy, A. Kumar, J. Sehouli, M. Lee, M. G. Inci-Turan,
F. Büttner

Saturday, April 29, 2023
GLOBAL HEALTH AND MOLECULAR DIAGNOSTICS AND PERSONALIZED THERAPIES IN ALL WOMEN’S CANCERS

sponsor of the day 04 28 gsk

INSIGHTS OF GLOBAL HEALTH PROGRAMS
Chairs: E. I. Braicu, G. Konecny

09:00 am
80 Minutes Around the World: Cervical Cancer Elimination Between Vision and Reality
S. Nasser, M. Gültekin, A. Ulrich, A. Stepanyan

CMC AWARD LECTURE

10:20 am
The Never-Ending HER2 Study
D. Slamon

OVERVIEW

10:50 am
Best of Clinical Trials in Rare Tumors
J. Grabowski
11:00 am
Coffee Break

INSIGHTS OF CLINICAL DEBATES
Chairs: J. Sehouli, J.-U. Blohmer, A. Wahner-Hendrickson

11:30 am
What is PARP Resistance and How to Overcome?
E. I. Braicu

LECTURES

11:50 am

Antibody Drug Conjugate (ADC)

  • Breast Cancer: J.-U. Blohmer
  • Gynecological Cancer: P. Harter
  • Discussion: J. Sehouli, J.-U. Blohmer, M. Beck, P. Harter
12:30 pm
Evolution of Synchronous Bilateral Breast Cancers Provide Insights into Interactions Between Host, Tumor and Immunity
F. Reyal
12:45 pm
Digital Patient
T. Pross
01:00 pm

Lunch Break

02:00 pm

SYMPOSIUM
(With kind support of GlaxoSmithKline)

Advancing Endometrial Cancer Treatment – Ongoing Developments and Growing Relevance of Biomarker Testing

  • The Growing Relevance of Upfront Biomarker Testing at Diagnosis of Endometrial Cancer
    X. Matias-Guiu
  • Current Developments in the Treatment of Advanced/Recurrent Endometrial Cancer
    M.R. Mirza

Chairs: J. Sehouli, J.-U. Blohmer, A. Wahner-Hendrickson

LECTURES
Chairs: J. Sehouli, J.-U. Blohmer, A. Wahner-Hendrickson

02:50 pm
Study Update GOG and ENGOT: Clinical Trial Landscape in GOG-ENGOT Collaboration
R. Coleman
03:10 pm
Learning Lessons From Long-Term Survivors with Gynecological Cancer
H. Woopen
03:30 pm
Molecular Tumor Conference
E. I. Braicu

CLOSING SESSION

04:00 pm
Presentation of the three Best Posters
04:20 pm
Closing Words and Farewell
04:30 pm
End of Program
agsdi-bookmark-star

CMC Master Course

Parallel to main program (09:00 am to 11:00 am)

Urological Complication Management in Gynecological Oncology
J. Neymeyer, R. Chekerov

agsdi-doctor

CMC Cadaver Course

Parallel to main program (08:00 am to 12:00 noon)

Gynecologic Oncology
M. Z. Muallem, A. Miranda, T. Jöns

agsdi-doctor

CMC Cadaver Course

Parallel to main program (01:00 pm to 05:00 pm)

Breast Cancer
J.-U. Blohmer, O. Camara, T. Jöns

Charité Mayo Conference